Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Front Cell Infect Microbiol ; 14: 1410015, 2024.
Article in English | MEDLINE | ID: mdl-38957797

ABSTRACT

Background: Tuberculosis (TB) persists as a global health challenge, with its treatment hampered by the side effects of long-term combination drug therapies and the growing issue of drug resistance. Therefore, the development of novel therapeutic strategies is critical. This study focuses on the role of immune checkpoint molecules (ICs) and functions of CD8+ T cells in the search for new potential targets against TB. Methods: We conducted differential expression genes analysis and CD8+ T cell functional gene analysis on 92 TB samples and 61 healthy individual (HI) samples from TB database GSE83456, which contains data on 34,603 genes. The GSE54992 dataset was used to validated the findings. Additionally, a cluster analysis on single-cell data from primates infected with mycobacterium tuberculosis and those vaccinated with BCG was performed. Results: The overexpression of LAG-3 gene was found as a potentially important characteristic of both pulmonary TB (PTB) and extrapulmonary TB (EPTB). Further correlation analysis showed that LAG-3 gene was correlated with GZMB, perforin, IL-2 and IL-12. A significant temporal and spatial variation in LAG-3 expression was observed in T cells and macrophages during TB infection and after BCG vaccination. Conclusion: LAG-3 was overexpressed in TB samples. Targeting LAG-3 may represent a potential therapeutic target for tuberculosis.


Subject(s)
Antigens, CD , CD8-Positive T-Lymphocytes , Lymphocyte Activation Gene 3 Protein , Mycobacterium tuberculosis , Tuberculosis , Humans , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/genetics , CD8-Positive T-Lymphocytes/immunology , Tuberculosis/immunology , Tuberculosis/microbiology , Animals , Antigens, CD/genetics , BCG Vaccine/immunology , Macrophages/immunology , Macrophages/microbiology , Interleukin-2/metabolism , Interleukin-2/genetics , Gene Expression Profiling , Tuberculosis, Pulmonary/immunology , Tuberculosis, Pulmonary/microbiology , Interleukin-12/genetics , Interleukin-12/metabolism , Perforin/genetics , Perforin/metabolism , Male
2.
Front Immunol ; 15: 1344272, 2024.
Article in English | MEDLINE | ID: mdl-38545114

ABSTRACT

Immune Checkpoint Inhibitors (ICIs) therapy has advanced significantly in treating malignant tumors, though most 'cold' tumors show no response. This resistance mainly arises from the varied immune evasion mechanisms. Hence, understanding the transformation from 'cold' to 'hot' tumors is essential in developing effective cancer treatments. Furthermore, tumor immune profiling is critical, requiring a range of diagnostic techniques and biomarkers for evaluation. The success of immunotherapy relies on T cells' ability to recognize and eliminate tumor cells. In 'cold' tumors, the absence of T cell infiltration leads to the ineffectiveness of ICI therapy. Addressing these challenges, especially the impairment in T cell activation and homing, is crucial to enhance ICI therapy's efficacy. Concurrently, strategies to convert 'cold' tumors into 'hot' ones, including boosting T cell infiltration and adoptive therapies such as T cell-recruiting bispecific antibodies and Chimeric Antigen Receptor (CAR) T cells, are under extensive exploration. Thus, identifying key factors that impact tumor T cell infiltration is vital for creating effective treatments targeting 'cold' tumors.


Subject(s)
Antibodies, Bispecific , Neoplasms , Humans , Immune Checkpoint Inhibitors/therapeutic use , Neoplasms/drug therapy , T-Lymphocytes , Immunotherapy/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...